0.5901

0.00% 0.00

After Hours: .59 -0.000100 -0.02%

Novabay Pharmaceuticals Inc (NBY)

Overview News Price History Discussions Forecast Stock Split

Novabay Pharmaceuticals Inc stock is traded at $0.5901, with a volume of 7,713. It is up +0.00% in the last 24 hours and down -1.65% over the past month. NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

Previous Close:

$0.5901

Open:

$0.5902

24h Volume:

7,713

Relative Volume:

0.14

Market Cap:

$3.43M

Revenue:

$14.64M

Net Income/Loss:

$-13.74M

P/E Ratio:

-0.0812

EPS:

-7.27

Net Cash Flow:

$-5.04M

1W Performance:

+0.44%

1M Performance:

-1.65%

6M Performance:

-16.77%

1Y Performance:

-90.33%

1-Day Range:

$0.59

$0.599

1-Week Range:

$0.55

$0.6116

52-Week Range:

$0.3611

$6.30

Novabay Pharmaceuticals Inc Stock (NBY) Company Profile

Name

Novabay Pharmaceuticals Inc

Sector

Healthcare (1174)

Industry

Biotechnology (670)

Phone

510-899-8800

Address

2000 Powell Street, Suite 1150, Emeryville, CA

Employee

Twitter

@NovaBayPharma

Next Earnings Date

2024-11-07

Latest SEC Filings

NBY's Discussions on Twitter

Compare NBY with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NBY Novabay Pharmaceuticals Inc	0.5901	3.42M	14.64M	-13.74M	-5.04M	-7.27
ONC Beigene Ltd Adr	236.86	24.29B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	447.18	110.94B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.2996	45.05M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	614.79	61.99B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	74.73	5.75B	0	-153.72M	-103.81M	-2.00

Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-18-19	Initiated	Ladenburg Thalmann	Buy
Jul-06-18	Reiterated	H.C. Wainwright	Buy
Nov-15-17	Reiterated	Laidlaw	Buy
Jun-05-17	Initiated	ROTH Capital	Buy
Mar-27-17	Initiated	Laidlaw	Buy
Feb-06-17	Initiated	Rodman & Renshaw	Buy
Mar-07-16	Downgrade	Maxim Group	Buy → Hold
Dec-14-15	Reiterated	Maxim Group	Buy
Apr-30-15	Resumed	Maxim Group	Buy
Mar-06-13	Initiated	Ascendiant Capital Markets	Strong Buy
Jan-03-08	Initiated	Dawson James	Speculative Buy

View All

Novabay Pharmaceuticals Inc Stock (NBY) Latest News

May 20, 2025

StockNews.com Begins Coverage on NovaBay Pharmaceuticals (NYSE:NBY) - Defense World

May 20, 2025

May 10, 2025

NovaBay fails to gain shareholder approval for dissolution - MSN

May 10, 2025

Apr 26, 2025

NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by Analysts at StockNews.com - Defense World

Apr 26, 2025

Apr 25, 2025

CNS Pharma Stock Price, Quotes and Forecasts | NASDAQ:CNSP - Benzinga

Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025

Apr 22, 2025

NovaBay Pharmaceuticals approves liquidation plan By Investing.com - Investing.com Canada

Apr 22, 2025

NovaBay Pharmaceuticals approves liquidation plan - Investing.com

Apr 22, 2025

Apr 16, 2025

Poplar Point Capital Partners acquires $39,503 in NovaBay shares - Investing.com Australia

Apr 16, 2025

Poplar Point Capital Partners increases stake in NovaBay Pharmaceuticals By Investing.com - Investing.com South Africa

Apr 16, 2025

Poplar Point Capital increases stake in NovaBay Pharmaceuticals - Investing.com Australia

Apr 16, 2025

Apr 15, 2025

Massive Stock Acquisition: Poplar Point Capital Partners Bets Big on NovaBay Pharma! - TipRanks

Apr 15, 2025

Poplar Point Capital Partners acquires $29,857 in NovaBay shares - Investing.com Australia

Apr 15, 2025

Poplar Point Capital increases stake in NovaBay Pharmaceuticals By Investing.com - Investing.com India

Apr 15, 2025

Poplar Point Capital Partners acquires $39,503 in NovaBay shares By Investing.com - Investing.com India

Apr 15, 2025

Poplar Point Capital Partners acquires $29,857 in NovaBay shares By Investing.com - Investing.com Canada

Apr 15, 2025

Novabay Pharmaceuticals sees $15,966 in recent stock acquisitions - Investing.com

Apr 15, 2025

Novabay Pharmaceuticals sees $15,966 in recent stock acquisitions By Investing.com - Investing.com UK

Apr 15, 2025

NovaBay Pharmaceuticals sees $67,700 stock acquisition by Poplar Point Capital - Investing.com India

Apr 15, 2025

Apr 02, 2025